Robaxin and Hyperplasia - a phase IV clinical study of FDA data

Summary:

Hyperplasia is reported as a side effect among people who take Robaxin (methocarbamol), especially for people who are female, 60+ old, also take Neurontin, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hyperplasia when taking Robaxin. It is created by eHealthMe based on reports of 8,252 people who have side effects when taking Robaxin from the FDA, and is updated regularly.

What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 9,109 Robaxin users. Check the latest studies of Robaxin.

What is Hyperplasia?

Hyperplasia (enlargement of an organ or tissue) is found to be associated with 314 drugs and 427 conditions by eHealthMe. Check the latest studies of Hyperplasia.

On Jul, 18, 2026

8,252 people reported to have side effects when taking Robaxin.
Among them, 32 people (0.39%) have Hyperplasia.

Among these 32 people:

What is the gender of people who have Hyperplasia when taking Robaxin? *

female: 59.38 %
male: 40.62 %

What is the age of people who have Hyperplasia when taking Robaxin? *

What are other drugs people take besides Robaxin? *

What are other side effects people have besides Hyperplasia? *

Stress And Anxiety: 29 people, 90.62%
Pain: 29 people, 90.62%
Spinal Osteoarthritis (joint cartilage loss in spine): 28 people, 87.50%
Osteonecrosis Of Jaw (death of bone of jaw): 27 people, 84.38%
Swallowing Difficulty: 26 people, 81.25%
Oedema Peripheral (superficial swelling): 23 people, 71.88%
Dyspnea (difficult or laboured breathing): 22 people, 68.75%
Pathological Fracture (broken bone caused by disease): 22 people, 68.75%
Intervertebral Disc Protrusion (spinal disc protrusion): 22 people, 68.75%
Arrhythmias (irregular heartbeat): 21 people, 65.62%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 15 people, 46.88%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 14 people, 43.75%
Breast Cancer: 14 people, 43.75%
Stress And Anxiety: 13 people, 40.62%
Bone Pain: 13 people, 40.62%
Bone Disorder: 13 people, 40.62%
Multiple Myeloma (cancer of the plasma cells): 11 people, 34.38%
Breast Cancer Metastatic: 6 people, 18.75%
Irritable Bowel Syndrome: 3 people, 9.38%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Robaxin and have Hyperplasia?

- Check whether Hyperplasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Robaxin:

Robaxin (9,109 reports)

Hyperplasia treatments and more:

Hyperplasia (1,530 reports)

Browse all side effects of Robaxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperplasia:

Hyperplasia (314 drugs)

Browse all the conditions that are associated with Hyperplasia:

Hyperplasia (427 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.